The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
Self-citationCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationForner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Self-citationK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Self-citationO'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Self-citationSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Self-citationHauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Lo, C.-M., Ngan, H., Tso, W.-K., Liu, C.-L., Lam, C.-M., Poon, R. T.-P., Fan, S.-T., & Wong, J. (2002) · Hepatology · doi:10.1053/jhep.2002.33156 · Cited by 2,613
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Hepatocellular carcinoma pathogenesis: from genes to environment
Farazi, P. A., & DePinho, R. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1934 · Cited by 1,979
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Liquid biopsy: monitoring cancer-genetics in the blood
Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,819
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Self-citationCasanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Llovet, J. M., Ducreux, M. P., Lencioni, R. A., Bisceglie, A. M. D., Dufour, J., Greten, T. F., Raymond, É., Roskams, T., Mazzaferro, V., Bruix, J., et al. (2012) · Cited by 1,488
Self-citationMicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., & Lynch, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0013 · Cited by 1,459
Self-citationGuichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I. B., Calderaro, J., Bioulac-Sage, P., Letexier, M., Degos, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2256 · Cited by 1,453
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
Gene expression in fixed tissues and outcome in hepatocellular carcinoma
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D. Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M. J., Lerner, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804525 · Cited by 1,286
Self-citationSWI/SNF nucleosome remodellers and cancer
Wilson, B. G., & Roberts, C. W. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3068 · Cited by 1,282
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Self-citationPhase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Llovet, J. M., Bustamante, J., Castells, A., Vilana, R., Del Carmen Ayuso, M., Sala, M., Brú, C., Rodés, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510290145 · Cited by 1,190
Self-citationSangro, B., Gomez-Martin, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., Riezu-Boj, J. I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.022 · Cited by 980
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
Lee, J.-S., Heo, J., Libbrecht, L., Chu, I.-S., Kaposi-Novak, P., Calvisi, D. F., Mikaelyan, A., Roberts, L. R., Demetris, A. J., Sun, Z., et al. (2006) · Nature Medicine · doi:10.1038/nm1377 · Cited by 953
Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 946
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
Lee, J.-S., Chu, I.-S., Heo, J., Calvisi, D. F., Sun, Z., Roskams, T., Durnez, A., Demetris, A. J., & Thorgeirsson, S. S. (2004) · Hepatology · doi:10.1002/hep.20375 · Cited by 922
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Zhou, D., Conrad, C., Xia, F., Park, J.-S., Payer, B., Yin, Y., Lauwers, G. Y., Thasler, W., Lee, J. T., Avruch, J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.026 · Cited by 913
American Association for the Study of Liver Diseases
Popper, H. (1960) · Gastroenterology · doi:10.1016/s0016-5085(60)80094-7 · Cited by 903
Resection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879
Self-citationFujimoto, A., Totoki, Y., Abe, T., Boroevich, K. A., Hosoda, F., Nguyen, H. H., Aoki, M., Hosono, N., Kubo, M., Miya, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2291 · Cited by 870
Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02654-4 · Cited by 847
Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Self-citationMicroRNA Expression, Survival, and Response to Interferon in Liver Cancer
Ji, J., Shi, J., Budhu, A., Yu, Z., Forgues, M., Roessler, S., Ambs, S., Chen, Y., Meltzer, P. S., Croce, C. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901282 · Cited by 802
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
Totoki, Y., Tatsuno, K., Covington, K. R., Ueda, H., Creighton, C. J., Kato, M., Tsuji, S., Donehower, L. A., Slagle, B. L., Nakamura, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.3126 · Cited by 781
Cheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 733
Self-citationFocal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Self-citationEpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma
Yamashita, T., Forgues, M., Wang, W., Kim, J. W., Ye, Q., Jia, H., Budhu, A., Zanetti, K. A., Chen, Y., Qin, L.-X., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6013 · Cited by 717
Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Conner, E. A., Lee, J., Factor, V. M., & Thorgeirsson, S. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.006 · Cited by 710
Muto, Y., Moriwaki, H., Ninomiya, M., Adachi, S., Saito, A., Takasaki, K. T., Tanaka, T., Tsurumi, K., Okuno, M., Tomita, E., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606133342402 · Cited by 668
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort†
Marrero, J. A., Fontana, R. J., Barrat, A., Askari, F., Conjeevaram, H. S., Su, G. L., & Lok, A. S. (2005) · Hepatology · doi:10.1002/hep.20636 · Cited by 637
Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Llovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 596
Self-citationZhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 576
Self-citationZhu, A. X., Kudo, M., Assenat, E., Cattan, S., Kang, Y.-K., Lim, H. Y., Poon, R. T. P., Blanc, J.-F., Vogel, A., Chen, C.-L., et al. (2014) · JAMA · doi:10.1001/jama.2014.7189 · Cited by 568
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Llovet, J. M., Peña, C. E. A., Lathia, C. D., Shan, M., Meinhardt, G., & Bruix, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2175 · Cited by 559
Self-citationGenomics and Signaling Pathways in Hepatocellular Carcinoma
Villanueva, A., Newell, P., Chiang, D., Friedman, S., & Llovet, J. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960171 · Cited by 556
Self-citationSantoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J. L., Van Vlierberghe, H., Trojan, J., Kolligs, F. T., Weiss, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70490-4 · Cited by 554
TGF- : Duality of Function Between Tumor Prevention and Carcinogenesis
Principe, D. R., Doll, J. A., Bauer, J., Jung, B., Munshi, H. G., Bartholin, L., Pasche, B., Lee, C., & Grippo, P. J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt369 · Cited by 523
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T. D., Gong, Z., Gao, H., Hao, K., Willard, M. D., Xu, J., et al. (2013) · Genome Research · doi:10.1101/gr.154492.113 · Cited by 523
Qin, S., Bai, Y., Lim, H. Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.-S., Bhudhisawasdi, V., Kang, W. K., Zhou, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5643 · Cited by 500
Zhu, A. X., Sahani, D. V., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Catalano, O. A., Sindhwani, V., Blaszkowsky, L. S., Yoon, S. S., Lahdenranta, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9908 · Cited by 477
How to obtain the P value from a confidence interval
Altman, D. G., & Bland, J. M. (2011) · BMJ · doi:10.1136/bmj.d2304 · Cited by 462
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.696 · Cited by 462
Targeted Therapies for Hepatocellular Carcinoma
Villanueva, A., & Llovet, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.006 · Cited by 449
Self-citationVillanueva, A., Hoshida, Y., Battiston, C., Tovar, V., Sia, D., Alsinet, C., Cornella, H., Liberzon, A., Kobayashi, M., Kumada, H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.006 · Cited by 447
Self-citationNotch signaling controls liver development by regulating biliary differentiation
Zong, Y., Panikkar, A., Xu, J., Antoniou, A., Raynaud, P., Lemaigre, F., & Stanger, B. Z. (2009) · Development · doi:10.1242/dev.029140 · Cited by 444
Sawey, E. T., Chanrion, M., Cai, C., Wu, G., Zhang, J., Zender, L., Zhao, A., Busuttil, R. W., Yee, H., Stein, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.040 · Cited by 436
Self-citationInactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma
Li, M., Zhao, H., Zhang, X., Wood, L. D., Anders, R. A., Choti, M. A., Pawlik, T. M., Daniel, H. D., Kannangai, R., Offerhaus, G. J. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.903 · Cited by 427
Ahn, S., Jang, S. J., Shim, J. H., Kim, D., Hong, S., Sung, C. O., Baek, D., Haq, F., Ansari, A. A., Lee, S. Y., et al. (2014) · Hepatology · doi:10.1002/hep.27198 · Cited by 424
Kaposi-Novak, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27236 · Cited by 398
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Llovet, J. M., & Hernandez-Gea, V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0547 · Cited by 397
Self-citationLlovet, J. M., Chen, Y., Wurmbach, E., Roayaie, S., Fiel, M. I., Schwartz, M., Thung, S. N., Khitrov, G., Zhang, W., Villanueva, A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.014 · Cited by 386
Self-citationA Mouse Model of Hepatocellular Carcinoma
Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G. D., Pham, T. A., Dillard-Telm, L., Tsai, S. P., Stephan, J.-P., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61177-7 · Cited by 359
Kudo, M., Han, G., Finn, R. S., Poon, R. T. P., Blanc, J.-F., Yan, L., Yang, J., Lu, L., Tak, W.-Y., Yu, X., et al. (2014) · Hepatology · doi:10.1002/hep.27290 · Cited by 355
Self-citationFGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Guagnano, V., Kauffmann, A., Wöhrle, S., Stamm, C., Ito, M., Barys, L., Pornon, A., Yao, Y., Li, F., Zhang, Y., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0210 · Cited by 347
A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection
Nault, J., De Reyniès, A., Villanueva, A., Calderaro, J., Rebouissou, S., Couchy, G., Decaens, T., Franco, D., Imbeaud, S., Rousseau, F., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.051 · Cited by 338
Self-citationCoulouarn, C., Factor, V. M., & Thorgeirsson, S. S. (2008) · Hepatology · doi:10.1002/hep.22283 · Cited by 332
Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice
Villanueva, A., Alsinet, C., Yanger, K., Hoshida, Y., Zong, Y., Toffanin, S., Rodriguez–Carunchio, L., Solé, M., Thung, S., Stanger, B. Z., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.002 · Cited by 318
Self-citationMuto, Y., Moriwaki, H., & Shiratori, Y. (1998) · Digestion · doi:10.1159/000051435 · Cited by 315
Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Minguez, B., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247131 · Cited by 310
Self-citationUHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma
Mudbhary, R., Hoshida, Y., Chernyavskaya, Y., Jacob, V., Villanueva, A., Fiel, M. I., Chen, X., Kojima, K., Thung, S., Bronson, R. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.003 · Cited by 309
Self-citationTargeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
Goyal, L., Muzumdar, M. D., & Zhu, A. X. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2791 · Cited by 307
Lachenmayer, A., Alsinet, C., Savic, R., Cabellos, L., Toffanin, S., Hoshida, Y., Villanueva, A., Minguez, B., Newell, P., Tsai, H.-W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2322 · Cited by 306
Self-citationPhase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
Thomas, M. B., Chadha, R., Glover, K., Wang, X., Morris, J., Brown, T., Rashid, A., Dancey, J., & Abbruzzese, J. L. (2007) · Cancer · doi:10.1002/cncr.22886 · Cited by 306
Intratumor Heterogeneity in Hepatocellular Carcinoma
Friemel, J., Rechsteiner, M., Frick, L., Böhm, F., Struckmann, K., Egger, M., Moch, H., Heikenwalder, M., & Weber, A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0122 · Cited by 296
Faivre, S., Raymond, E., Boucher, E., Douillard, J., Lim, H. Y., Kim, J. S., Zappa, M., Lanzalone, S., Lin, X., DePrimo, S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70171-8 · Cited by 290
Palmer, D. H., Midgley, R. S., Mirza, N., Torr, E. E., Ahmed, F., Steele, J. C., Steven, N. M., Kerr, D. J., Young, L. S., & Adams, D. H. (2009) · Hepatology · doi:10.1002/hep.22626 · Cited by 286
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
Rudalska, R., Dauch, D., Longerich, T., McJunkin, K., Wuestefeld, T., Kang, T.-W., Hohmeyer, A., Pesic, M., Leibold, J., von Thun, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3679 · Cited by 282
Desnoyers, L. R., Pai, R., Ferrando, R. E., Hötzel, K., Le, T., Ross, J., Carano, R., D'Souza, A., Qing, J., Mohtashemi, I., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210623 · Cited by 264
Transforming Growth Factor-β as a Therapeutic Target in Hepatocellular Carcinoma
Giannelli, G., Villa, E., & Lahn, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0243 · Cited by 263
Reig, M., Rimola, J., Torres, F., Darnell, A., Rodriguez-Lope, C., Forner, A., LLarch, N., Ríos, J., Ayuso, C., & Bruix, J. (2013) · Hepatology · doi:10.1002/hep.26586 · Cited by 257
YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression
Fitamant, J., Kottakis, F., Benhamouche, S., Tian, H. S., Chuvin, N., Parachoniak, C. A., Nagle, J. M., Perera, R. M., Lapouge, M., Deshpande, V., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.027 · Cited by 248
Self-citationMicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a
Toffanin, S., Hoshida, Y., Lachenmayer, A., Villanueva, A., Cabellos, L., Minguez, B., Savic, R., Ward, S. C., Thung, S., Chiang, D. Y., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.009 · Cited by 232
Self-citationButterfield, L. H., Ribas, A., Dissette, V. B., Lee, Y., Yang, J. Q., De la Rocha, P., Duran, S. D., Hernandez, J., Seja, E., Potter, D. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2856 · Cited by 232
Self-citationXiang, Q., Chen, W., Ren, M., Wang, J., Zhang, H., Deng, D. Y. B., Zhang, L., Shang, C., & Chen, Y. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2620 · Cited by 229
Chen, Y.-J., Yeh, S.-H., Chen, J.-T., Wu, C.-C., Hsu, M.-T., Tsai, S.-F., Chen, P.-J., & Lin, C.-H. (2000) · Gastroenterology · doi:10.1053/gast.2000.9373 · Cited by 229
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Reig, M., Torres, F., Rodriguez-Lope, C., Forner, A., LLarch, N., Rimola, J., Darnell, A., Ríos, J., Ayuso, C., & Bruix, J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.030 · Cited by 228
Tovar, V., Alsinet, C., Villanueva, A., Hoshida, Y., Chiang, D. Y., Solé, M., Thung, S., Moyano, S., Toffanin, S., Mínguez, B., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.01.015 · Cited by 223
Self-citationNewell, P., Toffanin, S., Villanueva, A., Chiang, D. Y., Minguez, B., Cabellos, L., Savic, R., Hoshida, Y., Lim, K. H., Melgar-Lesmes, P., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.028 · Cited by 222
Self-citationDasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
Finn, R. S., Bengala, C., Ibrahim, N., Roché, H., Sparano, J., Strauss, L. C., Fairchild, J., Sy, O., & Goldstein, L. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0288 · Cited by 220
Self-citationFinn, R. S., Kang, Y.-K., Mulcahy, M., Polite, B. N., Lim, H. Y., Walters, I., Baudelet, C., Manekas, D., & Park, J.-W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1991 · Cited by 215
Self-citationLachenmayer, A., Toffanin, S., Cabellos, L., Alsinet, C., Hoshida, Y., Villanueva, A., Minguez, B., Tsai, H.-W., Ward, S. C., Thung, S., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.009 · Cited by 205
Self-citationA Critical Role for Notch Signaling in the Formation of Cholangiocellular Carcinomas
Zender, S., Nickeleit, I., Wuestefeld, T., Sörensen, I., Dauch, D., Bozko, P., El-Khatib, M., Geffers, R., Bektas, H., Manns, M. P., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.019 · Cited by 200
Yeo, W., Chung, H. C., Chan, S. L., Wang, L. Z., Lim, R., Picus, J., Boyer, M., Mo, F. K. F., Koh, J., Rha, S. Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2395 · Cited by 199
Horwitz, E., Stein, I., Andreozzi, M., Nemeth, J., Shoham, A., Pappo, O., Schweitzer, N., Tornillo, L., Kanarek, N., Quagliata, L., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0782 · Cited by 185
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Khan, O. A., Fotheringham, S. A., Wood, V. H. J., Stimson, L., Zhang, C., Pezzella, F., Duvic, M. A., Kerr, D. J., & Thangue, N. B. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913912107 · Cited by 164
Zhu, A. X., Finn, R. S., Mulcahy, M., Gurtler, J., Sun, W., Schwartz, J. D., Dalal, R. P., Joshi, A., Hozak, R. R., Xu, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1442 · Cited by 159
Self-citationTai, W.-T., Cheng, A.-L., Shiau, C.-W., Huang, H.-P., Huang, J.-W., Chen, P.-J., & Chen, K.-F. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.047 · Cited by 158
O’Neil, B. H., Goff, L. W., Kauh, J. S. W., Strosberg, J., Bekaii‐Saab, T., Lee, R.-M., Kazi, A., Moore, D. T., Learoyd, M., Lush, R. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9432 · Cited by 151
Tao, Y., Ruan, J., Yeh, S., Lu, X., Wang, Y., Zhai, W., Cai, J., Ling, S., Gong, Q., Chong, Z., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108715108 · Cited by 134
Mutational landscape of HCC—the end of the beginning
Villanueva, A., & Llovet, J. M. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.243 · Cited by 123
Self-citationScholer‐Dahirel, A., Schlabach, M. R., Loo, A. T., Bagdasarian, L., Meyer, R., Guo, R., Woolfenden, S., Yu, K., Markovits, J., Killary, K. A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104182108 · Cited by 120
Toh, H. C., Chen, P., Carr, B. I., Knox, J. J., Gill, S., Ansell, P. J., McKeegan, E. M., Dowell, B. L., Pedersen, M., Qin, Q., et al. (2012) · Cancer · doi:10.1002/cncr.27758 · Cited by 115
Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Villanueva, A., & Llovet, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0151 · Cited by 105
Self-citationDituri, F., Mazzocca, A., Peidrò, F. J., Papappicco, P., Fabregat, I., Santis, F. D., Paradiso, A., Sabbà, C., & Giannelli, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067109 · Cited by 103
Maurel, M., Jalvy, S., Ladeiro, Y., Combe, C., Vachet, L., Sagliocco, F. A., Bioulac‐Sage, P., Pitard, V., Jacquemin‐Sablon, H., Zucman‐Rossi, J., et al. (2012) · Hepatology · doi:10.1002/hep.25994 · Cited by 103
Lim, H. Y., Heo, J., Choi, H. J., Lin, C.-Y., Yoon, J., Hsu, C., Rau, K., Poon, R. T. P., Yeo, W., Park, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3445 · Cited by 99
A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
Abou‐Alfa, G. K., Capanu, M., O'Reilly, E. M., Ma, J., Chou, J. F., Gansukh, B., Shia, J., Kalin, M. F., Katz, S. S., Abad, L. W., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.008 · Cited by 98
Shifting paradigms: the seeds of oncogene addiction
Sawyers, C. L. (2009) · Nature Medicine · doi:10.1038/nm1009-1158 · Cited by 93
VEGF Signaling in Cancer Treatment
Sia, D., Alsinet, C., Newell, P., & Villanueva, A. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990590 · Cited by 90
Self-citationFibroblast growth factor signaling in liver carcinogenesis
Sandhu, D. S., Baichoo, E., & Roberts, L. R. (2013) · Hepatology · doi:10.1002/hep.26679 · Cited by 87
AACR Cancer Progress Report 2013
Sawyers, C. L., Abate-Shen, C. T., Anderson, K. C., Barker, A. D., Baselga, J. M., Berger, N. A., Foti, M., Jemal, A., Lawrence, T. S., Li, C. I., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2107 · Cited by 81
Gene Signatures in the Management of Hepatocellular Carcinoma
Hoshida, Y., Moeini, A., Alsinet, C., Kojima, K., & Villanueva, A. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.05.003 · Cited by 79
Self-citation(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
Clinical Trials in Hepatocellular Carcinoma: An Update
Shen, Y., Lin, Z., Hsu, C., Hsu, C., Shao, Y., & Cheng, A. (2013) · Liver Cancer · doi:10.1159/000343850 · Cited by 69
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G., Yang, J., Kudo, M., Cai, J., Poon, R. T. P., Han, K., Tak, W. Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.4006 · Cited by 63
Self-citationSchmieder, R., Puehler, F., Neuhaus, R., Kissel, M., Adjei, A. A., Miner, J. N., Mumberg, D., Ziegelbauer, K. B., & Scholz, A. (2013) · Neoplasia · doi:10.1593/neo.13812 · Cited by 58
Diego, M., Lucas, A., de LIma, T., Milena, F.-S., Fernanda, P., & Gabriela, B. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu165.200 · Cited by 58
Calles, A., Kwiatkowski, N. P., Cammarata, B. K., Ercan, D., Gray, N. S., & Janne, P. A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.011 · Cited by 58
New designs for the selection of treatments to be tested in randomized clinical trials
Simon, R. M., Thall, P. F., & Ellenberg, S. S. (1994) · Statistics in Medicine · doi:10.1002/sim.4780130506 · Cited by 53
Faivre, S. J., Santoro, A., Kelley, R. K., Merle, P., Gane, E. J., Douillard, J., Waldschmidt, D., Mulcahy, M. F., Costentin, C. E., Mínguez, B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.lba173 · Cited by 45
The preclinical development of regorafenib for the treatment of colorectal cancer
Miura, K., Satoh, M., Kinouchi, M., Yamamoto, K., Hasegawa, Y., Philchenkov, A. A., Kakugawa, Y., & Fujiya, T. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.924923 · Cited by 43
Garon, E. B., Balmanoukian, A. S., Hamid, O., Hui, R., Gandhi, L., Leighl, N. B., Gubens, M. A., Goldman, J. W., Lubiniecki, G. M., Emancipator, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.14aacriaslc-a20 · Cited by 17
Finn, R. S., Aleshin, A., Zhao, D., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-3858 · Cited by 14
Self-citationBitzer, M., Horger, M., Ganten, T. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.4115 · Cited by 9
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationLlovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Self-citationZhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Self-citationMolecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Self-citationGenetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Self-citation
Metadata
- Authors
- Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2015-06-09
- Volume
- 12
- Issue
- 7
- Pages
- 408-424
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W1863396492
- Cited by
- 621
- References
- 159
- FWCI
- 11.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.